UK Parkinson's Disease Consortium - UKPDC
- Principal Investigators
- Research Groups
- Degenerating neurons
- Department of Molecular Neuroscience, UCL
- Department of Clinical Neuroscience, UCL
- MRC Protein Phosphorylation Unit, Dundee
- MRC Centre for Developmental and Biomedical Genetics, Sheffield
- Eisai Ltd
- Clinical Movement Disorders Group, UCL
- MRC Centre for Neuromuscular Diseases, UCL
- Neurodegeneration, UCL
- Neurophysiology of Human Development, UCL
- Pathophysiology of Human Movement Disorders, UCL
- Queen Square Brain Bank, UCL
- Reta Lila Weston Institute of Neurological Studies, UCL
- Sobell Department of Motor Neuroscience and Movement Disorders, UCL
- Unit of Functional Neurosurgery, UCL
- UCL Consortium for Mitochondrial Research
- UCL Genetics Institute (UGI)
- UCL Genomics
- Neurogenetics Unit, UCLH
- Neurometabolic Unit, UCLH
- Lysosomal Storage Disorders Unit, Royal Free
- School of Medicine and Dentistry, Aberdeen
- PD Med, Birmingham
- Cambridge Bristol Toronto Hamburg Neurodegenerative Disease Consortium
- Cambridge Centre for Brain Repair
- The Movement Disorders Group, Cambridge
- MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff
- MRC Centre for Regenerative Medicine, Edinburgh
- MRC Sudden Death Brain and Tissue Bank, Edinburgh
- The Institute of Cancer Research
- Bioinformatics, Statistical Genetics & Epigenetics, KCL
- MRC Toxicology Unit, Leicester
- Wellcome Trust Case Control Consortium
- WT/MRC Neurodegenarative Diseases Initiative
- Wellcome Trust Sanger Institute
- AMC Department of Neurology, Amsterdam
- Department of Clinical Genetics, VUMC
- Laboratory of Neurogenetics, NIA/NIH
- French National Institute of Health and Medical Research (Inserm)
- Brain & Spine Institute, Paris
- Centre-de-Physiopathologie-de-Toulouse-Purpan (CPTP)
- Department for Neurodegenerative Diseases, Tübingen
- Contact us
A study published in Brain, led by researchers
at UCL Institute of Neurology, has shown that genetic mutations which
cause a decrease in dopamine
production in the brain and lead to a form of childhood-onset Dystonia,
also play a role in the development of Parkinson’s disease.
The new Leonard Wolfson Experimental Neurology Centre (LWENC) has opened for clinical studies and trials
In this paper Claudia Manzoni studies how fibroblast
cells from people with Parkinson’s disease caused by mutations in LRRK2
react to starvation. Although the changes are quite subtle, there are
differences between the way that fibroblasts that contain mutant LRRK2
respond to being starved – suggesting that there may be changes in the
way that these cells regulate a key process called autophagy (a term
which comes from the greek meaning to eat yourself, and is one of the
ways that cells get rid of waste and recycle proteins and organellles).
Research led by consortium researchers Dr Helene Plun-Favreau (UCL Institute of Neurology) and Dr Alex Whitworth (University of Sheffield), and collaborator Dr Heike Laman (University of Cambridge), has discovered how genetic mutations linked to Parkinson’s disease might play a key role in the death of brain cells, potentially paving the way for the development of more effective drug treatments. In the new study, published in Nature Neuroscience, the team of cross-institutional researchers showed how defects in the Parkinson’s gene Fbxo7 cause problems with mitophagy. More...
Mutations in LRRK2 are the most common genetic cause of Parkinson’s disease. Here, Claudia Manzoni talks about her research (funded by the Rosetrees Trust and the Michael J. Fox Foundation) into what LRRK2 might be doing within the cell: Parkinson’s disease is a brain illness that afflicts 1 in 500 people in the UK. High profile patients, such as the actor Michael J Fox, the boxer Muhammad Ali and the late Pope John Paul II, have raised public awareness of Parkinson’s and its devastating impact. More...
Pathophysiology of Human Movement Disorders, UCL
Movement disorders cover a diverse range of neurological conditions from Parkinson’s disease to tremor and dystonia. They are thought of primarily as disorders of basal ganglia function, but the consequences of such dysfunction and the contribution of other brain areas are only beginning to be understood. Our current research has three broad aims: 1) To improve and develop clinical categorisation of movement disorders by researching electrophysiological “signatures” or biomarkers of particular disorders, 2) to use electrophysiological and psychophysical techniques to explore the pathophysiology of different movement disorders and 3) to research the possible application of rTMS in the treatment of movement disorders.
The Pathophysiology of Human Movement Disorders lab at the Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology is based in number 33 Queen Square with access to state of the art electrophysiology facilities.
We use the following techniques:
- Transcranial magnetic stimulation to measure various parameters of cortical excitability.
- Repetitive transcranial magnetic stimulation, paired associative stimulation to explore brain plasticity.
- Psychophysical assessments of reaction time, attention and learning.
Page last modified on 17 mar 11 11:12